Chad M Moles

Mr. Chad M Moles

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Surgery
Verified
Journal Article
Closed access
SBSwathi Balaji
Swathi Balaji
NHNate Han
Nate Han
CMChad M Moles
Chad M Moles
ASAimen F. Shaaban
Aimen F. Shaaban
PBPaul L. Bollyky
Paul L. Bollyky
SKSundeep Keswani
Sundeep Keswani

1 July 2014 in Journal of Surgical Research
Verified
Journal Article
Closed access
SBSwathi Balaji
Swathi Balaji
CMChad M Moles
Chad M Moles
SBSukanta S. Bhattacharya
Sukanta S. Bhattacharya
MLMaria LeSaint
Maria LeSaint
YDYashu Dhamija
Yashu Dhamija
SKSundeep G. Keswani
Sundeep G. Keswani

21 October 2024 in Viruses
Verified
Journal Article
Open access
PDF file
CMChad M Moles
Chad M Moles
RBRupsa Basu
Rupsa Basu
PWPeter Weijmarshausen
Peter Weijmarshausen
BHBrenda Ho
Brenda Ho
MFManal Farhat
Manal Farhat
BSBruce F. Smith
Bruce F. Smith
Vesicular stomatitis virus (VSV) is a prototype RNA virus that has been instrumental in advancing our understanding of viral molecular biology and has applications in vaccine development, cancer therapy, antiviral screening, and more. Current VSV genome plasmids for purchase or contract virus services provide limited options for modification, restricted to predefined cloning sites and insert locations. Improved methods and tools to engineer VSV will unlock further insights into long-standing virology questions and new opportunities for innovative therapies. Here, we report the design and construction of a full-length VSV genome. The 11,161 base pair synthetic VSV (synVSV) was assembled from four modularized DNA fragments. Following rescue and titration, phenotypic analysis showed no significant differences between natural and synthetic viruses. To demonstrate the utility of a synthetic virology platform, we then engineered VSV with a foreign glycoprotein, a common use case for studying viral entry and developing anti-virals. To show the freedom of design afforded by this platform, we then modified the genome of VSV by rearranging the gene order, switching the positions of VSV-P and VSV-M genes. This work represents a significant technical advance, providing a flexible, cost-efficient platform for the rapid construction of VSV genomes, facilitating the development of innovative therapies.


26 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CMChad M Moles
Chad M Moles
RBRupsa Basu
Rupsa Basu
PWPeter Weijmarshausen
Peter Weijmarshausen
BHBrenda Ho
Brenda Ho
MFManal Farhat
Manal Farhat
BSBruce F. Smith
Bruce F. Smith
Vesicular stomatitis virus (VSV) is a prototype RNA virus that has been instrumental in advancing our understanding of viral molecular biology and has applications in vaccine development, cancer therapy, antiviral screening, and more. Current VSV genome plasmids for purchase or contract virus services provide limited options for modification, restricted to predefined cloning sites and insert locations. Improved methods and tools to engineer VSV will unlock further insights in long-standing virology questions and new opportunities for innovative therapies. Here, we report the design and construction of a full-length VSV genome. The 11,161 base pair synthetic VSV (synVSV) was assembled from four modularized DNA fragments. Following rescue and titration, phenotypic analysis showed no significant differences between natural and synthetic viruses. To demonstrate the utility of a synthetic virology platform, we then engineered VSV with a foreign glycoprotein, a common use case for studying viral entry and developing anti-virals. To show the freedom-of-design afforded by this platform, we then modified the genome of VSV by rearranging the gene order, switching the positions of VSV-P and VSV-M genes. This work represents a significant technical advance, providing a flexible, cost-efficient platform for the rapid construction of VSV genomes, facilitating the development of innovative therapies.